Auszug
Als idiopathische neonatale Hepatitis (INH) bezeichnet man eine neonatale cholestatische Erkrankung, bei der die Vielzahl anderer ätiologischer Ursachen (⊡ Tab. 16.1) ausgeschlossen werden konnten. Histopathologisch ist sie durch sog. Riesenzellen gekennzeichnet und wurde deshalb auch als »Riesenzellhepatitis« bezeichnet. Zunächst wurde die INH in 30–40% aller Fälle mit neonataler Cholestase diagnostiziert, wegen verbesserter diagnostischer Möglichkeiten nimmt ihr Anteil in jüngeren Studien jedoch deutlich ab - was darauf hindeutet, dass die INH keine eigenständige Entität, sondern einen Sammeltopf verschiedener Formen der neonatalen Cholestase darstellt.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
Literatur
Altman RP, Abramson S (1985) Potential errors in the diagnosis and surgical management of neonatal jaundice. J Pediatr Surg 20: 529–534
Crofts DJ, Michel VJ, Rigby AS, Tanner MS, Hall DM, Bonham JR (1999) Assessment of stool colour in community management of prolonged jaundice in infancy. Acta Paediatr 88: 969–974
Desmet V (2001) The cholangiopathies. In: Suchy FJ, Sokol RJ, Balistreri WF (eds) Liver disease in children. Lippincott, Williams & Wilkins, Philadelphia, pp 39–62
Deutsch GH, Sokol RJ, Stathos TH, Knisely AS (2001) Proliferation to paucity: evolution of bile duct abnormalities in a case of Alagille syndrome. Pediatr Dev Pathol 4: 559–563
Fung KP, Lau SP (1990) Differentiation between extrahepatic and intrahepatic cholestasis by discriminant analysis. J Paediatr Child Health 26: 132–135
Melter M, Meier PN, Nietzmann T et al. (in Vorbereitung) ERCP in neonatal obstructive cholestasis: a prospective study for the diagnosis of biliary atresia.
Norton KI, Glass RB, Kogan D, Lee JS, Emre S, Shneider BL (2002) MR cholangiography in the evaluation of neonatal cholestasis: initial results. Radiology 222: 687–691
Sokol RJ, Mack C, Narkewicz MR, Karrer FM (2003) Pathogenesis and outcome of biliary atresia: current concepts. J Pediatr Gastroenterol Nutr 37: 4–21
Literatur
Chardot C, Carton M, Spire-Bendelac N, Le Pommelet C, Golmard JL, Auvert B (1999) Prognosis of biliary atresia in the era of liver transplantation: French national study from 1986 to 1996. Hepatology 30: 606–611
Davenport M, De Ville de Goyet J, Stringer MD et al. (2004) Seamless management of biliary atresia in England and Wales (1999–2002). Lancet 363: 1354–1357
Davenport M, Puricelli V, Farrant P et al. (2004) The outcome of the older (> or =100 days) infant with biliary atresia. J Pediatr Surg 39: 575–581
Grabhorn E, Schulz A, Helmke K et al. (2004) Short-and long-term results of liver transplantation in infants aged less than 6 months. Transplantation 78: 2341–2352
Nio M, Ohi R, Miyano T, Saeki M, Shiraki K, Tanaka K (2003) Five-and 10-year survival rates after surgery for biliary atresia: a report from the Japanese Biliary Atresia Registry. J Pediatr Surg 38: 997–1000
Perlmutter DH, Shepherd RW (2002) Extrahepatic biliary atresia: a disease or a phenotype? Hepatology 35: 297–304
Petersen C (2004) Surgery in biliary atresia — futile or futuristic? Eur J Pediatr Surg 14: 226–229
Petersen C (2006) Pathogenesis and treatment opportunities for biliary atresia. Clin Liver Dis 10: 73–88
Reuben A (2003) The sensei of Sendai: correcting the uncorrectable. Hepatology 37: 952–955
Sokol RJ, Mack C, Narkewicz MR, Karrer FM (2003) Pathogenesis and outcome of biliary atresia: current concepts. J Pediatr Gastroenterol Nutr 37: 4–21
Literatur
Arnell H, Nemeth A, Anneren G, Dahl N (1997) Progressive familial intrahepatic cholestasis (PFIC): evidence for genetic heterogeneity by exclusion of linkage to chromosome 18q21–q22. Hum Genet 100(3–4): 378–381
Colliton RP, Bason L, Lu FM, Piccoli DA, Krantz ID, Spinner NB (2001) Mutation analysis of Jagged1 (JAG1) in Alagille syndrome patients. Hum Mutat 17(2): 151–152
de Vree JM, Jacquemin E, Sturm E et al. (1998) Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc Natl Acad Sci USA 95(1): 282–287
Emond JC, Whitington PF (1995) Selective surgical management of progressive familial intrahepatic cholestasis (Byler’s disease). J Pediatr Surg 30(12): 1635–1641
Jacquemin E, Hermans D, Myara A et al. (2001) Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis. Hepatology 25(3): 519–523
Jansen PL, Muller M, Sturm E (2001) Genes and cholestasis. Hepatology 34: 1067–1074
Jansen PL, Strautnieks SS, Jacquemin E et al. (1999) Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis. Gastroenterology 117(6): 1370–1379
Kamath BM, Loomes KM, Oakey RJ et al. (2002) Facial features in Alagille syndrome: specific or cholestasis facies? Am J Med Genet 112(2): 163–170
Kamath BM, Spinner NB, Emerick KM et al. (2004) Vascular anomalies in Alagille syndrome: a significant cause of morbidity and mortality. Circulation 109(11): 1354–1358
Kasahara M, Kiuchi T, Inomata Y et al. (2003) Living-related liver transplantation for Alagille syndrome. Transplantation 75(12): 2147–2150
Klomp LW, Vargas JC, van Mil SW et al. (2004) Characterization of mutations in ATP8B1 associated with hereditary cholestasis. Hepatology 40(1): 27–38
Lykavieris P, Crosnier C, Trichet C, Meunier-Rotival M, Hadchouel M (2003) Bleeding tendency in children with Alagille syndrome. Pediatrics 111(1): 167–170
Piccoli DA, Spinner NB (2001) Alagille syndrome and the Jagged1 gene. Semin Liver Dis 21(4): 525–534
Strautnieks SS, Bull LN, Knisely AS et al. (1998) A gene encoding a liverspecific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet 20(3): 233–238
Literatur
Balistreri WF, Kader HH, Ryckman FC, Heubi JE, Setchell KDR and UDCA Study Group (1992) Ursodeoxycholic acid therapy in paediatric patients with chronic cholestasis. In: Lentze M, Reichen R (eds) Paediatric cholestasis — Novel approaches to treatment. Kluwer Academic, Dordrecht Boston London, pp 333–343
Bergasa NV, Alling DW, Talbot TL, Wells MC, Jones EA (1999) Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study. J Am Acad Dermatol 41: 431–434
Borgeat A, Wilder-Smith OH, Mentha G (1993) Subhypnotic doses of propofol relieve pruritus associated with liver disease. Gastroenterology 104: 244–247
Cotting J, Lentze MJ, Reichen J (1990) Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and longstanding cholestasis. Gut 31: 918–921
de Caestecker JS, Jazrawi RP, Petroni ML, Northfield TC (1991) Ursodeoxycholic acid in chronic liver disease. Gut 32: 1061–1065
Heuman DM (1993) Hepatoprotective properties of ursodeoxycholic acid. Gastroenterology 104: 1865–1870
Hollands CM, Rivera-Pedrogo FJ, Gonzalez-Vallina R, Loret-de-Mola O, Nahmad M, Burnweit CA (1998) Ileal exclusion for Byler’s disease: an alternative surgical approach with promising early results for pruritus. J Pediatr Surg 33: 220–224
Jacquemin E, Hermans D, Myara A et al. (1997) Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis. Hepatology 25: 519–523
Jones EA, Bergasa NV (1990) The pruritus of cholestasis: from bile acids to opiate agonists. Hepatology 11: 884–887
Jones EA, Bergasa NV (2000) Evolving concepts of the pathogenesis and treatment of the pruritus of cholestasis. Can J Gastroenterol 14: 33–40
Kardorff R, Melter M, Rodeck B, Brodehl J (1996) Langfristige Ursodeoxycholsäurebehandlung cholestatischer Lebererkrankungen des Kindesalters — klinische und biochemische Effekte. [Long-term ursodeoxycholic acid treatment of cholestatic liver diseases in childhood — clinical and biochemical effects.] Klin Pädiatr 208: 118–122
Melter M, Rodeck B, Kardorff R et al. (2000) Progressive familial intrahepatic cholestasis: Partial biliary diversion normalizes serum lipids and improves growth in noncirrhotic patients. Am J Gastroenterol 95: 3522–3528
Muller C, Pongratz S, Pidlich J et al. (1998) Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind crossover trial. Eur J Gastroenterol Hepatol 10: 865–870
Neff GW, O’Brien CB, Reddy KR et al. (2002) Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. Am J Gastroenterol 97: 2117–2119
Oelberg DG, Lester R (1986) Cellular mechanisms of cholestasis. Annu Rev Med 37: 297–317
Rebhandl W, Felberbauer FX, Turnbull J et al. (1999) Biliary diversion by use of the appendix (cholecystoappendicostomy) in progressive familial intrahepatic cholestasis. J Pediatr Gastroenterol Nutr 28: 217–219
Riikonen S, Savonius H, Gylling H, Nikkila K, Tuomi AM, Miettinen TA (2000) Oral guar gum, a gel-forming dietary fiber relieves pruritus in intrahepatic cholestasis of pregnancy. Acta Obstet Gynecol Scand 79: 260–264
Rust C, Sauter GH, Oswald M et al. (2000) Effect of cholestyramine on bile acid pattern and synthesis during administration of ursodeoxycholic acid in man. Eur J Clin Invest 30: 135–139
Whitington PF, Whitington GL (1988) Partial external diversion of bile for the treatment of intractable pruritus associated with intrahepatic cholestasis. Gastroenterology 95: 130–136
Yerushalmi B, Sokol RJ, Narkewicz MR, Smith D, Karrer FM (1999) Use of rifampin for severe pruritus in children with chronic cholestasis. J Pediatr Gastroenterol Nutr 29: 442–447
Yoshikawa M, Tsujii T, Matsumura K et al. (1992) Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology 16: 358–364
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Melter, M., Petersen, C., Sturm, E. (2008). Neonatale Cholestase. In: Rodeck, B., Zimmer, KP. (eds) Pädiatrische Gastroenterologie, Hepatologie und Ernährung. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-73969-2_16
Download citation
DOI: https://doi.org/10.1007/978-3-540-73969-2_16
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-73968-5
Online ISBN: 978-3-540-73969-2
eBook Packages: Medicine (German Language)